Ta Hsung Tung

Array ( [id] => 16090535 [patent_doc_number] => 20200199254 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-25 [patent_title] => IDENTIFICATION OF VSIG8 AS THE PUTATIVE VISTA RECEPTOR (V-R) AND USE THEREOF TO PRODUCE VISTA/VSIG8 AGONISTS AND ANTAGONISTS [patent_app_type] => utility [patent_app_number] => 16/531968 [patent_app_country] => US [patent_app_date] => 2019-08-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 88025 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16531968 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15145009 [patent_doc_number] => 20190350982 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-21 [patent_title] => Activation of Marrow Infiltrating Lymphocytes in Hypoxic Alternating with Normoxic Conditions [patent_app_type] => utility [patent_app_number] => 16/526656 [patent_app_country] => US [patent_app_date] => 2019-07-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6647 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -39 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16526656 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16582880 [patent_doc_number] => 20210017282 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-21 [patent_title] => TARGETED BINDING AGENTS AGAINST B7-H1 [patent_app_type] => utility [patent_app_number] => 16/519614 [patent_app_country] => US [patent_app_date] => 2019-07-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45845 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16519614 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15618861 [patent_doc_number] => 20200079835 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-12 [patent_title] => B7-RELATED NUCLEIC ACIDS AND POLYPEPTIDES USEFUL FOR IMMUNOMODULATION [patent_app_type] => utility [patent_app_number] => 16/516225 [patent_app_country] => US [patent_app_date] => 2019-07-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40423 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16516225 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15993491 [patent_doc_number] => 20200172616 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-04 [patent_title] => HUMAN ANTI-PD-1, PD-L1, AND PD-L2 ANTIBODIES AND USES THEREFOR [patent_app_type] => utility [patent_app_number] => 16/506840 [patent_app_country] => US [patent_app_date] => 2019-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37805 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16506840 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18233205 [patent_doc_number] => 11597754 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-03-07 [patent_title] => Use of the CD2 signaling domain in second-generation chimeric antigen receptors [patent_app_type] => utility [patent_app_number] => 16/460221 [patent_app_country] => US [patent_app_date] => 2019-07-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 23998 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 134 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16460221 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15556869 [patent_doc_number] => 20200062846 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-27 [patent_title] => IMMUNOPOTENTIATIVE COMPOSITION [patent_app_type] => utility [patent_app_number] => 16/459392 [patent_app_country] => US [patent_app_date] => 2019-07-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12917 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16459392 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14993817 [patent_doc_number] => 20190315866 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-17 [patent_title] => Antibodies Directed Against ICOS and Uses Thereof [patent_app_type] => utility [patent_app_number] => 16/452984 [patent_app_country] => US [patent_app_date] => 2019-06-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16125 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16452984 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15556873 [patent_doc_number] => 20200062848 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-27 [patent_title] => HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1) [patent_app_type] => utility [patent_app_number] => 16/448721 [patent_app_country] => US [patent_app_date] => 2019-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40753 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16448721 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14963175 [patent_doc_number] => 20190309065 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-10 [patent_title] => METHODS AND COMPOSITIONS FOR THE TREATMENT OF PERSISTENT INFECTIONS AND CANCER BY INHIBITING THE PROGRAMMED CELL DEATH 1 (PD-1) PATHWAY [patent_app_type] => utility [patent_app_number] => 16/445130 [patent_app_country] => US [patent_app_date] => 2019-06-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20523 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16445130 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15800229 [patent_doc_number] => 20200123257 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-23 [patent_title] => ICOS BINDING PROTEINS [patent_app_type] => utility [patent_app_number] => 16/441474 [patent_app_country] => US [patent_app_date] => 2019-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 48173 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16441474 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15866295 [patent_doc_number] => 20200140551 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-07 [patent_title] => ICOS BINDING PROTEINS [patent_app_type] => utility [patent_app_number] => 16/440137 [patent_app_country] => US [patent_app_date] => 2019-06-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 48163 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 91 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16440137 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14963187 [patent_doc_number] => 20190309071 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-10 [patent_title] => METHODS OF TREATING CANCER USING ANTI-PD-L1 ANTIBODIES AND ANTIANDROGENS [patent_app_type] => utility [patent_app_number] => 16/437402 [patent_app_country] => US [patent_app_date] => 2019-06-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21088 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -70 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16437402 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14868071 [patent_doc_number] => 20190284277 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-19 [patent_title] => ANTI-LAG3 ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/433263 [patent_app_country] => US [patent_app_date] => 2019-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43815 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -39 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16433263 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16429490 [patent_doc_number] => 10829557 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-11-10 [patent_title] => Anti-B7-H1 antibodies for treating tumors [patent_app_type] => utility [patent_app_number] => 16/418488 [patent_app_country] => US [patent_app_date] => 2019-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 29 [patent_no_of_words] => 13545 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 136 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16418488 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15646835 [patent_doc_number] => 20200085947 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-19 [patent_title] => VISTA MODULATORS FOR DIAGNOSIS AND TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 16/411488 [patent_app_country] => US [patent_app_date] => 2019-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 91116 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16411488 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14746855 [patent_doc_number] => 20190256601 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-22 [patent_title] => ANTI-PD-1 ANTIBODIES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/399262 [patent_app_country] => US [patent_app_date] => 2019-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42105 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16399262 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17393390 [patent_doc_number] => 11242392 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-08 [patent_title] => Anti-vista antibodies and fragments [patent_app_type] => utility [patent_app_number] => 16/395585 [patent_app_country] => US [patent_app_date] => 2019-04-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 39 [patent_figures_cnt] => 94 [patent_no_of_words] => 22980 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 120 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16395585 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14682141 [patent_doc_number] => 20190240185 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-08 [patent_title] => TREATMENT WITH ANTI ErbB2 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/392300 [patent_app_country] => US [patent_app_date] => 2019-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16380 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16392300 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14685115 [patent_doc_number] => 20190241672 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-08 [patent_title] => INTRAVESICAL THERAPY FOR BLADDER CANCER [patent_app_type] => utility [patent_app_number] => 16/388379 [patent_app_country] => US [patent_app_date] => 2019-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6109 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16388379 [rel_patent_id] =>[rel_patent_doc_number] =>)